Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes

Blood

Volumn 91, Issue 9, 1998, Pages 3366-3367

  Perez Simon J A ^b   Garcia Sanz R ^b   Tabernero, M D ^b   Almeida, J ^b   Gonzalez M ^b   Fernandez Calvo J ^b   Moro, M J ^b   Hernandez J M ^b   San Miguel, J F ^a   Orfao A ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; LACTATE DEHYDROGENASE;

ANEUPLOIDY; ARTICLE; BONE MARROW CELL; CELL SURVIVAL; CHROMOSOME 13; CHROMOSOME 9; DIAGNOSTIC VALUE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; METAPHASE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NUMERICAL CHROMOSOME ABERRATION; PRIORITY JOURNAL; PROGNOSIS;

EID: 2642617778     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.9.3366     Document Type: Article

References (43)

1. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A: C-reactive protein and β2microglobulin produce a simple and powerful myeloma staging system. Blood 80:733, 1992
2. San Miguel JF, García-Sanz R. González M, Moro MJ, Hernández JM, Ortega F, Borrego D, Carnero M, Casanova F, Jiménez R, Portero JA, Orfão A: A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 85:448, 1995
3. Durie BGM, Young LA, Salmon SE: Human myeloma in vitro colony growth: Interrelationship between drug sensitivity, cell kinetics, and patient survival duration. Blood 61:929, 1983
4. Boccadoro M, Massaia M, Dianziani U, Pileri A: Multiple myeloma: Biological and clinical significance of bone marrow plasma cell labeling index. Haematologica (Pavia) 72:171, 1987
5. García-Sanz R, Orfão A, González M, Moro MJ, Hernández JM, Ortega F, Borrego D, Carnero M, Casanova F, Jiménez R, Portero JA, San Miguel JF: Prognostic implications of DNA aneuploidy in a series of 156 untreated MM patients. Br J Haematol 90:106, 1995
6. Greipp PR, Lust JA, O'Fallon M, Katzmann JA, Witzig TE, Kyle RA: Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81:3382, 1993
7. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789, 1997
8. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer J: Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250, 1995
9. Dewald GW, Kyle RA, Hicks GA, Greipp PRP: The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia or amyloidosis. Blood 66:380, 1985
10. Durie BGM: Cellular and molecular genetics features of myeloma and related disorders. Hematol Oncol Clin North Am 6:463, 1992
11. Sawyer JR, Waldron JA, Jagannath S, Barlogie B: Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82:41, 1995
12. Laï JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T: Improved cytogenetics in Multiple myeloma. Blood 9:2490, 1995
13. Cuneo A, Balsamo R, Roberti MG, Bardi A, Piva N, Balboni M, Bigoni R, Rigolin GM, Castoldi G: Interleukin-3 plus interleukin-6 may improve chromosomal analysis of multiple myeloma: Cytological and cytogenetic evidence in thirty-four patients. Cancer Genet Cytogenet 90:171, 1996
14. Drach J, Schuster J, Nowotny H, Angerler J, Rosenthal F, Fiegl M, Rothermundt C, Gsur A, Jager U, Heinz R: Multiple myeloma: High incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 55:3854, 1995
15. Tabernero D, San Miguel JF, García-Sanz R, Nájera L, Garcia-Isidoro M, Pérez-Simón JA, Gonzalez M, Wiegant J, Raap AK, Orfão A: Incidence of chromosome numerical changes in multiple myeloma. Fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol 149:153, 1996
16. Bladé J, San Miguel JF, Alcalá A, Maldonado J, Sanz MA, García-Conde J, Moro MJ, Alonso C, Besalduch J, Zubizarreta A, Besses C, González Brito G, Hernández-Martín J, Fernández-Calvo J, Rubio D, Ortega F, Jiménez R, Colominas P, Faura MV, Font L, Tortosa J, Domingo A, Fontanillas M, Rozman C, Estapé C: Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: A randomized multicentric study of 487 patients. J Clin Oncol 11:1165, 1993
17. San Miguel JF, González M, Gascón A, Moro MJ, Hernández JM, Ortega F, Jiménez R, Guerras L, Romero M, Casanova F, Sanz MA, Sánchez J, Portero JA, Orfão A: Immunophenotype heterogeneity of multiple myeloma: Influence on the biology and clinical course of the disease. Br J Haematol 77:185, 1992
18. Orfão A, García-Sanz R, López-Berges MC, Vidriales MB, González M, Caballero MD, San Miguel JF: A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry 17:332, 1994
19. García-Sanz R, Gonzalez M, Orfão A, Moro J, Hernández M, Borrego D, Carnero M, Casanova F, Bárez A, Jiménez R, Portero JA, San Miguel JF: Analysis of natural killer associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol 93:81, 1996
20. Wiegant J, Ried T, Nederlof PM, Van der Ploeg M, Tanke HJ, Raap AK: In situ hybridization with fluoresceinated DNA. Nucleic Acids Res 19:3237, 1991
21. Arnoldus EPJ, Noordemeer IA, Peters ACB, Boormolen JHC, Bots TAM, Raap AK, Van der Ploeg M: Interphase cytogenetics of brain tumors. Gene Chromosom Cancer 3:101, 1991
22. Vindelov LL, Christehnsen IBJ, Jensen G, Nissen NI: Limits of detection of nuclear DNA abnormalities by flow cytometric DNA analysis. Results obtained by a set of methods for sample storage, staining and internal standardization. Cytometry 3:332, 1983
23. Cox DR, Oakes D: Analysis of Survival Data. London, UK, Chapman and Hall, 1981
24. Dixon WJ: Biomedical-Data Package: Statistical Software. Berkley, CA, University of California, 1983
25. Morgan RJ, Gonchoroff NJ, Katzmann JA, Witzig TE, Kyle RA, Greipp PR: Detection of hypodiploidy using multi-parameter flow cytometric analysis: A prognostic indicator in multiple myeloma. Am J Hematol 30:195, 1989
26. Smith L, Barlogie B, Alexanian R: Biclonal and hypodiploid multiple myeloma. Am J Med 80:841, 1985
27. San Miguel JF, Almeida J, Ocqueteau M, Orfão A: Detection of two subpopulations of plasma cells in MGUS patients: Utility in the differential diagnosis with MM. Blood 88:640a, 1996 (abstr, suppl 1)
28. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase 4 inhibitor p16INK4 In multiple human cancers. Nature 368:753, 1994
29. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Sckolnik MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436, 1994
30. Ng MHL, Chung YF, Lo KW, Wickham NWR, Lee JCK, Huang DP: Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89:2500, 1997
31. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler PH: Human p53 localized at short arm of chromosome 17. Nature 319:783, 1986
32. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM: Localization of gene for human p53 to band 17p13. Nature 320:84, 1986
33. Prokocimer M, Rotter V: Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages. Blood 84:2391, 1994
34. Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P, Gu W, Nilsson K, Knowles D, Boccadoro M, Pileri A, Dalla-Favera R: Inactivation of tumor-supressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 8:758, 1994
35. Foulkes WD, Ragoussis J, Stamp GW, Allan GJ, Travsdale J: Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer 67:551, 1993
36. Tibiletti MG, Bernasconi B, Taborelli M, Furlan D, Fabbri A, Franchi M, Taramelli R, Trubia M, Capella C: Involvement of chromosome 6 in endometrial cancer. Br J Cancer 75:1831, 1997
37. Sheng ZM, Marchetti A, Buttitta F, Champeme MH, Campani D, Bistocchi M, Lidereau R, Callahan R: Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. Br J Cancer 73:144, 1996
38. Dao DD, Sawyer JR, Epstein J, Hoover RG, Barlogie B, Tricot G: Deletion of the retinoblastoma gene in multiple myeloma. Leukemia 8:1280, 1994
39. Zandecki M, Façon T, Preudhomme C, Vanrumbeke M, Vachee A, Quesnel B, Lai JL, Cosson A, Fenaux P: The retinoblastoma gene (Rb-1) status in multiple myeloma: A report on 35 cases. Leuk Lymphoma 18:497, 1995
40. Juge-Morineau N, Mellerin MP, Francois S, Rapp MJ, Harousseau JL, Amiot M, Bataille R: High incidence of deletion but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br J Haematol 91:664, 1995
41. Maestro R, Piccinin S, Doglioni C, Gasparotto D, Vukosavljevic T, Sulfaro S, Barzan L, Boiocchi M: Chromosome 13q deletion mapping in head and neck squamous cell carcinomas: Identification of two distinct regions of preferential loss. Cancer Res 56:1146, 1996
42. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ: Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 56:1142, 1996
43. Liu Y, Szekely L, Grander D, Soderhall S, Juliusson G, Gahrton G, Linder S, Einhorn S: Chronic Lymphocytic leukemia cells with allelic deletion at 13q14 commonly have one intact Rb-1 gene: Evidence for a role of an adjacent locus. Proc Natl Acad Sci USA 90:8697, 1993